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Abstract
Introduction
Colorectal cancer (CRC) screening rates are suboptimal, particu-
larly among the uninsured and the under-insured and among rural
and African American populations. Little guidance is available for
state-level decision makers to use to prioritize investment in evid-
ence-based interventions to improve their population’s health. The
objective of this study was to demonstrate use of a simulation
model that incorporates synthetic census data and claims-based
statistical models to project screening behavior in North Carolina.
Methods
We used individual-based modeling to simulate and compare in-
tervention costs and results under 4 evidence-based and stakehold-
er-informed intervention scenarios for a 10-year intervention win-
dow, from January 1, 2014, through December 31, 2023. We com-
pared the proportion of people living in North Carolina who were
aged 50 to 75 years at some point during the window (that is, age-
eligible for screening) who were up to date with CRC screening
recommendations across intervention scenarios, both overall and
among groups with documented disparities in receipt of screening.
Results
We estimated that the costs of the 4 intervention scenarios con-
sidered would range from $1.6 million to $3.75 million. Our mod-
el showed that mailed reminders for Medicaid enrollees, mass me-
dia  campaigns  targeting African Americans,  and colonoscopy
vouchers for the uninsured reduced disparities in receipt of screen-
ing by 2023, but produced only small increases in overall screen-
ing rates (0.2–0.5 percentage-point increases in the percentage of
age-eligible adults who were up to date with CRC screening re-
commendations). Increased screenings ranged from 41,709 addi-
tional life-years up to date with screening for the voucher inter-
vention to 145,821 for the mass media intervention. Reminders
mailed to Medicaid enrollees and the mass media campaign for
African Americans were the most  cost-effective interventions,
with costs per additional life-year up to date with screening of $25
or less. The intervention expanding the number of endoscopy fa-
cilities cost more than the other 3 interventions and was less ef-
fective in increasing CRC screening.
Conclusion
Cost-effective CRC screening interventions targeting observed
disparities are available, but substantial investment (more than
$3.75 million) and additional approaches beyond those considered
here are required to realize greater increases population-wide.
Introduction
Colorectal  cancer  (CRC)  is  the  third  leading  cause  of  cancer
deaths in the United States. Nearly 140,000 people are diagnosed
with the disease each year and more than 50,000 die from the dis-
ease (1). Screening can detect CRC at a localized stage when treat-
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ment is most effective and can detect and remove precancerous
polyps,  thereby  reducing  incidence  and  death  (2,3).  National
guidelines recommend routine CRC screening for average-risk
adults aged 50 through 75 years (2). However, a national survey
based on self-report from 2010 suggests that only 64.5% (4) of
age-eligible people meet these guidelines. These self-reported data
probably overestimated actual screening (5). In addition, screen-
ing rates were lower among the uninsured compared to the in-
sured and among people with low incomes or low educational
levels compared to their higher income and education counter-
parts (4,6). Because of the large differences in screening rates and
corresponding disease outcomes across these subpopulations (4),
addressing disparities in receipt of screening is essential.
Tested interventions have increased screening in populations with
observed disparities in receipt of CRC screening. For example,
one multifaceted intervention supported screening among low-in-
come patients in community health centers through mailed inform-
ation, screening reminders, and outreach by patient navigators (7).
However,  such interventions have not  been implemented on a
wide scale and have not been compared with alternatives to de-
termine their relative cost and effectiveness and taken together,
their efficiency. Decision makers need this information for inter-
ventions to inform their recommendations, policies, and decisions
about investment in CRC screening programs. Because such de-
cisions are often made at the state level, we chose to evaluate CRC
interventions in a single state, North Carolina. The factors that
shape screening preferences, access, and, ultimately, receipt and
disparities in screening suggest that intervention programs should
be tailored to current levels of health care, population characterist-
ics, and access to care in a given geographic context or when tar-
geting a specific subpopulation. Our objective was to compare the
impact and cost-effectiveness of 4 evidence-based interventions
for  increasing  CRC  screening  and  reducing  disparities  in
guideline-concordant CRC screening in North Carolina and to
present a process that could be replicated to inform decision mak-
ing about CRC interventions in other states.
Methods
We used an individual-based simulation model to estimate the rel-
ative effects of 4 evidence-based approaches to increasing CRC
screening among age-eligible (aged 50 to 75 years at some point
during the intervention window of January 1, 2014, and Decem-
ber 31,  2023) North Carolina residents in whom disparities in
guideline-concordant receipt of screening were observed — most
notably  among  subgroups  by  sex,  race,  insurance  status,  and
county of residence (6). Individual-based modeling is computer
modeling in which events are simulated, with realistic uncertainty
built in, for each heterogeneous individual in a specified popula-
tion based on predefined rules (eg, incidence rates, mortality rates,
interaction between individuals or with the environment) over a
specified period to estimate population-level outcomes over time
or the impact of simulated interventions. We reviewed the literat-
ure and US Preventive Services Task Force guidelines (2) to de-
velop and refine 4 intervention scenarios through a series of inter-
views with 19 decision makers and other local stakeholders (ie,
clinicians, public health professionals, payers, researchers, state
health officials, and experts from the Centers for Disease Control
and Prevention). Although the same intervention scenarios we se-
lected may not be the ones preferred in other settings, they were
among the most common approaches documented in the literature
and were endorsed by our stakeholders. These interventions con-
sisted of mailed reminders to a registry of Medicaid enrollees, ex-
pansion of endoscopy facilities to increase overall access to care, a
mass media campaign targeting African Americans, and screening
colonoscopy vouchers for the uninsured.
We used a model that is an extension of a validated CRC screen-
ing  model  based  on  the  MISCAN-COLON  model  (8,9).  Our
primary change to the model was to simulate a complete, realistic
population of all North Carolina residents who were age-eligible
(aged 50–75 y) for routine CRC screening at some point during
the 10-year intervention period, and to project each individual’s
screening  method  and  compliance  with  recommended  CRC
screening on the basis of multilevel, multivariable statistical mod-
els,  estimated by using rich North Carolina public and private
claims  data.  The  individual-based  model  effectively  projects
known  screening  patterns  to  the  full  population,  first  in  this
claims-based “screening-as-usual” scenario representing currently
observed status-quo patterns of CRC screening receipt. This mod-
el provided a virtual world in which we implemented the 4 inter-
vention scenarios, each targeting synthetic individuals with differ-
ent characteristics, to learn about their relative cost, impact on
CRC screening receipt, and efficiency — defined as cost per addi-
tional life-year up to date with screening recommendations. This
study was approved by the University of North Carolina Chapel
Hill institutional review board.
Model overview and outcomes
The model simulated the full life course of all North Carolina res-
idents who were age-eligible for CRC screening at some point
during our  study’s  10-year  intervention window of  January 1,
2014, through December 31, 2023. We simulated a “screening-as-
usual” scenario (existing screening practices) and compared its
CRC screening outcomes to those under hypothetical intervention
scenarios. The model simulated a person’s status, over time, as up
to date with testing, defined as having had a fecal occult blood test
(FOBT) (most observed fecal tests were FOBTs) within the past
year or a colonoscopy within the past 10 years. To model actual
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screening at the beginning of the intervention window, simulated
screening began when all people included in the synthetic popula-
tion were age-eligible – even if this occurred prior to January 1,
2014.  Increases  in  screening  resulting  from the  interventions
began January 1, 2014, and ended December 31, 2023, ensuring
the full impact of any screening colonoscopies received in the last
year of the intervention window were fully included in interven-
tion effects.
Primary outcomes were the percentage of age-eligible people who
were up to date with recommended CRC screening after 10 years
of intervention (a point-in-time measure) and the number of addi-
tional life-years synthetic individuals were up to date with CRC
screening over the entire study period under each intervention
scenario (4 interventions simulated independently as well as com-
bination scenarios) compared with the screening-as-usual scenario;
the total cost of each intervention (independently simulated); and
the incremental cost per additional life-year synthetic individuals
were up to date with recommended CRC screening because of the
intervention. Secondary outcomes were reduction in disparities in
the percentage of age-eligible people up to date with CRC screen-
ing recommendations, by sex, race, insurance type, and geograph-
ic location.
Simulated population
We sought to simulate routine screening on the basis of real-world
(observed) combinations of known determinants of CRC screen-
ing: age, sex, race, insurance type, and geographic location (6). A
primary input to the model was a synthetic population of North
Carolina residents, which was created using data from the Ameri-
can Community Survey Public Use Microdata Sample, 2005–2010
(www.census.gov/acs/www).  A  total  of  3,918,469  simulated
people were age-eligible for screening sometime during the inter-
vention window. Table 1 presents a snapshot of the population on
the first day of the intervention window. We assigned each person
in the synthetic population a life expectancy based on their ob-
served age, race, and sex, according to life tables (10). Insurance
coverage was absent from the synthetic population and was as-
signed probabilistically.
Receipt of CRC screening
We calculated  predicted  probabilities  for  receipt  of  any  CRC
screening test and the type of screening method (colonoscopy vs
FOBT) for synthetic individuals on the basis of their demographic
characteristics by using 2 sets of nested insurance-claims–derived
logistic regression models (6). Models of both screening test use
and type of test were multilevel, with county-level (eg, number of
primary care providers per 10,000 residents) and individual-level
attributes (eg, insurance type, race, sex) predicting whether or not
a CRC screening test was received, and, if so, what method. Meth-
od was limited to colonoscopy or FOBT because of the very small
proportion of people in North Carolina who received other types
of CRC screening. The analytical sample used to estimate these
statistical models included all North Carolina residents turning 50
between January 1, 2003, and December 31, 2008, who were con-
tinuously enrolled in private health plans, Medicaid, or Medicare
during this 6-year period. Predicted probabilities estimated from
these statistical models were scaled up proportionally for all indi-
viduals to adjust claims-based estimates of overall screening on
the basis of national survey data, adjusted for self-report bias (5).
Diagnostic testing and surveillance
Diagnostic testing and surveillance, although not the focus of this
study,  were  simulated  with  the  objective  of  estimating  up-to-
datedness attributable to positive results from routine screenings
and follow-up diagnostic colonoscopies triggered by simulated in-
terventions. As such, people receiving FOBTs who had positive
test results were presumed to have been offered diagnostic colono-
scopies, and 75% were presumed to receive follow-up colono-
scopy (8). Following the detection and removal of precancerous
polyps, they entered a period of surveillance during which they
were offered colonoscopies every 3 years, and adherence was pre-
sumed to be 80% (8). After 2 negative colonoscopies, determined
probabilistically, these people transitioned from surveillance back
to their original schedule of routine screening.
Analysis
The model was implemented in AnyLogic, version 6.9 (Product
Marketing Corp). Model testing consisted of independent code re-
view,  extreme-value  testing,  behavior-reproduction  testing  in
which simulated trends were compared with available data, and re-
view of model behavior with context experts (11). To ensure that
differences in outcomes were due to interventions and not random-
ness, innovative “common patients” methods developed in engin-
eering were implemented to  ensure common random numbers
were used for  all  variables unrelated to intervention scenarios
across the screening-as-usual and intervention scenarios (12).
Each intervention was implemented individually and in combina-
tions. Combination intervention scenarios added the 4 interven-
tions, one at a time, based on their impact on life-years up to date
with screening, from greatest to least impact. Incremental cost-ef-
fectiveness  was  defined  as  the  ratio  of  the  difference  in  cost
between the intervention scenario and screening-as-usual scenario,
divided by the difference in life-years up to date between the inter-
vention scenario and screening as usual.
For the secondary analysis, the impact of each intervention scen-
ario in sub-populations was estimated to quantify the ability of
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each intervention to address screening disparities in the interven-
tion compared with screening-as-usual scenarios 10 years after the
interventions were implemented. Given that  simulated cohorts
were extremely large, 10 replications were run to assess variabil-
ity in outcomes; mean results were reported.
Intervention scenarios
Four intervention approaches were developed and quantified based
on systematic literature review and extensive stakeholder inter-
views and were designed to reflect a balance of approaches under
consideration in North Carolina with evidence about how to ad-
dress observed CRC screening disparities. The costs of each inter-
vention were estimated from the state’s perspective and reflected
the expected resources needed for implementation of each inter-
vention scenario above and beyond what would be covered under
usual care (for example, the cost of the endoscopy expansion pro-
gram included the cost of increasing the number of screening fa-
cilities, but not the cost of additional CRC screening that would
result  from increased access and would be paid under existing
mechanisms).  With  state-supported  intervention  programs  in
mind, all 4 interventions were designed to cost less than a maxim-
um budget of $4 million over 10 years. Detailed cost estimates are
presented in Table 2.
The intervention consisting of mailing of reminders to the Medi-
caid registry involved mailing initial letters to all Medicaid en-
rollees turning 50 that provided information on the importance of
CRC screening, recommended screening guidelines, information
on available screening options, and instructions for scheduling a
screening test or requesting additional information. A similar let-
ter was sent each year for the 10-year study period to all Medicaid
enrollees who were not up to date with CRC screening according
to claims data, excepting people who were diagnosed with CRC.
Reflecting data limitations, 10% of those who underwent CRC
screening were assumed to have been erroneously sent a reminder
because of imperfect data or data retrieval.  Based on evidence
from prior trials, being sent a reminder leads to a 5–percentage-
point increase in the probability of being screened, recognizing
that the effect of the mailing is greatest among those who receive
and read the mailing and that there are many failure points for this
intervention between being sent a mailing and receiving screening
(13–15).
The endoscopy expansion intervention involved providing finan-
cial incentives for 6 new endoscopy facilities to be located in zip
codes of greatest need, defined as the areas with the greatest dens-
ity of unscreened adults residing more than 25 miles from a facil-
ity who could more readily reach a facility if it were located with-
in 25 miles or less. The effect on screening resulted from the in-
creased chance of screening associated with a decreased distance
to a screening facility and increased number of screenings in the
person’s county of residence in the statistical models — though
these estimated effects were small and varied by insurance type
(6).
The  mass  media  intervention,  which  was  targeted  to  African
Americans, involved an annual month-long mass media campaign
using tailored television, print, and radio advertisements to com-
municate the importance of CRC screening. On the basis of evid-
ence, the campaign was assumed to reach 80% of African Ameri-
cans  state-wide,  resulting  in  a  2–percentage-point  increase  in
screening probability among those who were reached by the ad-
vertisements in that year (16–23). A residual effect was assumed
to increase the probability of screening among 40% of non-Afric-
an Americans by 1 percentage point (24). The persuasive impact
of advertising decays quickly, so no lasting impact was assumed
(25).
The fourth intervention simulated a statewide program in which
uninsured people turning 50 were provided a voucher for a free
colonoscopy until a maximum of 50 vouchers were used in each of
the 10 intervention years. The vouchers provided payment dir-
ectly to the endoscopy facility and included the initial cost of the
colonoscopy and any polyp removal and biopsy.
Results
Under the calibrated screening-as-usual scenario, 53.0% in 2014
and 54.0% in 2023 of age-eligible people were estimated to be up-
to-date with CRC testing. Medicaid mailed reminders, mass me-
dia, and vouchers for the uninsured all produced modest increases
in up-to-datedness overall (Figure and Table 3). When comparing
the 4 interventions’ effects, the mailed reminder and mass media
campaign produced the largest increases in CRC screening. The
voucher program and endoscopy expansion had smaller, but posit-
ive, effects. Costs per additional life-year up to date ranged from
less than $15 (mailed reminder) to more than $200 (expansion of
endoscopy facilities). The combination of the mailed reminder and
mass media interventions was most cost-effective,  assuming a
state’s willingness to pay approximately $20 per additional life-
year up to date and invest $5.3 million overall.
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Figure. Cost-effectiveness efficiency frontier presenting the additional life-
years up to date with recommended colorectal cancer screening among the
population age-eligible for screening during the intervention window (x-axis)
and  intervention  cost  (y-axis)  under  each  of  4  intervention  scenarios,
compared with screening as usual (existing screening). Results are presented
for  each  intervention  alone  and  for  combination  scenarios  in  which
interventions are added, one at a time, based on their estimated intervention
cost per additional life-year up to date (in 2014 US dollars). The dashed line
indicates single and combined intervention scenarios that are not dominated
by other intervention scenarios, where “dominated” means that the scenario
is both more expensive and has less impact. Dollar values inside the figure
indicate cost of each additional life-year up to date.
 
Table 3 presents the impact of each intervention, independently,
on the percentage of people up to date with CRC screening in
2023 among all  subpopulations  studied.  Mailed reminders  re-
duced  the  screening  gap  between  Medicaid  enrollees  and  the
privately insured from 6.7 to 2.1 percentage points. The mass me-
dia  intervention  reduced  the  gap  between  whites  and  African
Americans from 3.5 to 2.4 percentage points. The voucher for un-
insured reduced the gap between privately insured and uninsured
residents from 42.4 to 41.3 percentage points. Expansion of endo-
scopy facilities did not increase overall screening or reduce the
gap between counties with the highest and lowest screening rates.
Discussion
Analysis  of  the  individual-based  simulation  model  identified
mailed reminders for Medicaid enrollees and a mass media cam-
paign targeting African Americans to be the most effective and
cost-effective options to increase CRC screening, assuming soci-
ety is willing to pay approximately $25 per additional life-year a
person is up to date with recommended screening. The proposed
voucher program for the uninsured should be adopted only if ad-
dressing disparities in screening between uninsured and insured
individuals is particularly important or if willingness to pay ap-
proaches $100 per additional life-year up to date with screening.
Endoscopy expansion, as conceptualized, was relatively ineffect-
ive and strongly surpassed by the other interventions. Although
some  interventions  were  cost-effective,  the  interventions  ex-
amined required 10-year investments ranging from $1.6 million to
$3.75 million but had small effects individually, and in combina-
tion, on the state’s overall screening rates.
This study focused on the cost per additional life-year a person
was up to date with CRC screening recommendations. This metric
has the advantage of better weighting differential intervention ef-
fects on receipt of FOBT and colonoscopy, given the various re-
commended frequencies of these tests. Little guidance existed pre-
viously on what constitutes a reasonable cost per additional life-
year up to date with CRC screening. To provide some perspective,
a cost of $25 per life-year up to date would be equivalent to in-
creasing the cost of annual FOBT from its current cost of approx-
imately $20 to  $45 each year,  or  the  cost  of  one colonoscopy
(which covers a person for 10 years) from its current cost of ap-
proximately $750 to $1,000. Previous studies have indicated that
costs of these screening test would be within the range considered
acceptable for such interventions (26).
Unlike most CRC models, the comparator scenario used in this
study was based on state-specific data and explanatory statistical
models, providing a current understanding of who is and who is
not being screened and with which screening method in a full age-
eligible population, and what might be gained through alternative
interventions. This understanding can be used to inform interven-
tion program planning aimed at improving CRC screening rates
within resource constraints while simultaneously addressing dis-
parities, as illustrated here. Although other methodological ap-
proaches, such as longitudinal, multiple case studies (27,28) and
pragmatic trials (29) can also be used to gain valuable insights
about what works where and why, such studies are expensive and
take time. Because models like ours can compare multiple inter-
vention programs, such approaches can guide efforts toward more
efficiently closing gaps in CRC screening in a timely manner and
can support prioritizing state-level planning and research funding,
helping health officials and policy makers set more achievable
goals (30).
This model has some limitations. First, not all factors that affect
CRC screening (eg, changes in reimbursement policy or techno-
logy) could be modeled. Second, as with any simulation model,
there is uncertainty about key model parameters, such as interven-
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tion cost and effectiveness. Additionally, the lack of a full cost ac-
counting study limits the ability to reflect on long-term costs or
savings that may result from these interventions. Specifically, this
analysis does not account for the costs of cancer treatment (those
costs resulting from detection and also those costs prevented), so
the full economic impact or effects on illness and death are not re-
flected. Finally, the ability to measure the outcome is affected by
both inaccuracies in claims-based and self-reported data, which we
attempted to address by proportionally increasing all claims data-
based screening probabilities to match estimates based on self-re-
port (adjusted for self-report bias as described in the Methods sec-
tion). This important limitation of existing data needs to be con-
sidered in establishing and evaluating national targets, including
Healthy People 2020 targets, and in evaluating our ability to reach
them.
Despite these limitations, a model such as this provides a useful
foundation for informing intervention approaches, and it can be
updated to support further integration of new data on costs, screen-
ing assumptions, and emerging evidence on best practices, with re-
analysis informing ongoing intervention decisions. For example,
decision makers might be interested in revising the mailed remind-
er if it was thought to be less expensive to integrate material into
ongoing broad mailings at the state level (eg, to drivers for license
and registration renewal) or more effective to include a fecal im-
munochemical  test  in  the  mailing.  Alternatively,  as  evidence
mounts about the feasibility of mobile endoscopy units, an inter-
vention based on these units might be favored to enhance access.
After  updating  intervention  scenarios,  analyses  such  as  those
presented here could be replicated or extended to update policy re-
commendations or address new population health, clinical, or ser-
vice delivery questions. Across settings, various intervention scen-
arios can be developed to reflect priorities and preferences for in-
terventions. Over time, as progress is made toward addressing dis-
parities and closing gaps in screening, updating and re-analyzing
the model could chart a dynamic course toward efficiently meet-
ing established population health targets. Along the way, as out-
side factors change (eg, insurance expansion, changing reimburse-
ment policies,  new clinical guidelines),  data should be re-ana-
lyzed  to  determine  whether  intervention  programs  should  be
altered. Also, analysis of a model such as ours could support lo-
gistical planning in North Carolina and elsewhere – for example,
by examining whether existing endoscopy capacity is sufficient in
light of Medicaid eligibility expansion.
Using simulation models to compare hypothetical programs to in-
crease CRC screening is an important but underused strategy when
planning programs to reduce the burden of CRC and related dis-
parities in receipt of screening. Using state-specific and published
data, the scientific literature, and decision-maker input to formu-
late intervention scenarios, our analysis of an individual-based
simulation model suggested that mailed reminders to Medicaid be-
neficiaries and a mass media campaign targeted to African Ameri-
cans would be among the most cost-effective strategies available
to both increase the proportion of persons up to date with CRC
testing and to decrease disparities in CRC screening by income,
insurance status, and race in North Carolina with moderate invest-
ment. However, to ensure that greater proportions of the popula-
tion are screened (eg, 70%–80%), substantially higher investment
would be required in these or other interventions.
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Tables
Table 1. Demographic Characteristics of the Simulated Population of North Carolina Residents Age-Eligiblea for Colorectal Cancer Screening on January 1, 2014b
Characteristic Overall Aged 50–64 yc Aged 65–75 yc
Population, n 2,782,559 1,844,279 938,280
Sex
Male 47.7 48.0 47.1
Female 52.3 52.0 52.9
Race
White 77.0 75.3 80.3
African American 18.4 19.5 16.4
Otherd 4.6 5.2 3.3
Insurance
Uninsured 10.3 15.5 0.1
Private 49.2 73.9 0.4
Medicare only 31.6 3.5 86.9
Medicaid only 3.1 4.7 0.0
Medicare and Medicaid 5.8 2.4 12.6
a Aged 50 to 75 years.
b Values are percentages unless otherwise indicated.
c Age on January 1, 2014.
d Asian/Pacific Islanders, American Indian/Alaska Natives, and other racial minorities. Hispanic ethnicity is distributed across racial groups.
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Table 2. Cost Parameters for Intervention Scenarios, Cost-Effectiveness Analysis of Four Simulated Colorectal Cancer Screening Interventions, North Carolina, Janu-
ary 1, 2014–December 31, 2023
Cost Component Cost Estimate, $ Notes and Sources
Mailing reminder to Medicaid enrollees
Develop registry and reminder content (one-time) 10,000 Programmer and physicians’ time (author assumption)
Programming time to identify enrollees 200/y Author assumption
Materials 0.71/reminder Postage, paper, inka
Staff time to prepare and mail reminders 3,850/y 200 h staff time
Expansion of the number of endoscopy facilities
Financial incentive to locate 6 facilities in underserved areas 500,000/facility Author assumption based on North Carolina stakeholder interviews
Mass media campaign targeting African Americans
Purchase advertising for month-long campaign 332,000/y Estimated from a similar statewide mass media campaign in North
Carolina promoting seat belt use, in which advertising purchases were
$52,907 per week for newspaper advertisements in 15 daily
newspapers (1 advertisement per week for 4 weeks), 1,406 television
spots, and 3,154 radio spotsb 1996 costs were adjusted for inflation to
2014 using the Consumer Price Index.
Content development (one-time) 368,000 From campaign promoting seat belt use described abovec
Free colonoscopy voucher for uninsured
Voucher for colonoscopy 750/person 2013 Medicare physician fee schedule (www.cms.gov) for Healthcare
Common Procedure Coding System codes 45378, 45380, 45383,
45384, 45385, G0121
a Data sources: Lee et al (14) and Lewis et al (15).
b Data source: Broadwater et al (17).
c Data source: Williams et al (16).
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Table 3. Simulated Age-Eligiblea North Carolina Population Up to Date With Recommended Colorectal Cancer Screening on December 31, 2023
Variable
Screening as
Usualb, %
Percentage-Point Change in Testing Under Each Intervention Scenario Compared With Screening as
Usual
Mailed Reminder Endoscopy Expansion Mass Media Voucher for Uninsured
Overall 54.0 +0.4 +0.0 +0.5 +0.2
By sex
Male 55.5 +0.3 +0.0 +0.6 +0.2
Female 53.0 +0.5 +0.0 +0.5 +0.1
By race
White 55.4 +0.3 +0.0 +0.3 +0.1
African American 51.9 +0.9 +0.1 +1.4 +0.2
Otherc 48.1 +0.5 +0.0 +0.4 +0.4
By insurance
Private 57.0 +0.0 +0.0 +0.5 +0.0
Medicaid 50.3 +4.6 +0.2 +0.8 +0.0
Medicare 52.0 +0.0 +0.0 +0.4 +0.0
Medicare and Medicaid 44.8 +3.5 +0.1 +0.7 +0.0
Uninsured 14.6 +0.0 +0.0 +0.6 +1.2
By county
Gap (maximum–minimum)d 15.7 −0.1 +0.0 +0.2 +0.0
a Aged 50 to 75 years.
b Existing screening practices.
c No distinctions by ethnicity (ie, Hispanic) possible in claims data.
d The disparity in percentage of population up to date with colorectal cancer screening between counties with the highest (maximum) and lowest (minimum) per-
formance under screening as usual and the percentage point change in that gap under each intervention scenario.
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